Launching a drug development company with novel technology from academia
Our corporate group has worked with hundreds of entrepreneurs at this stage to help them optimally and efficiently select and form the appropriate legal entity
Brian M. Connelly
Of Counsel
Brian’s knowledge and experience in the life sciences industry bridges the gap between business and law. His diverse background makes him a valuable partner for the firm and our clients.
Brian joined Faber over 15 years ago after working in both legal and business development roles within an S&P500 diagnostics company. Brian has also served as the CEO of TheracosBio, LLC, a Massachusetts-based commercial stage pharmaceutical company. Prior to that, Brian co-founded IncreVet, Inc., which developed the first FDA-approved oral treatment for feline diabetes before being acquired in early 2022.
Brian assists clients within the biopharmaceutical industry on a broad range of commercial and corporate matters but has unique expertise in assisting clients with CMC-related matters and supply chain and distribution arrangements. In addition, Brian frequently counsels clients in connection with the leasing and build out of specialized laboratory and manufacturing space. He has drafted and negotiated leases in major life sciences markets across the United States, including the Greater Boston/Cambridge areas, New Jersey, Philadelphia, Raleigh, San Diego and Seattle.
Brian assists clients within the biopharmaceutical industry on a broad range of commercial and corporate matters but has unique expertise in assisting clients with CMC-related matters and supply chain and distribution arrangements. In addition, Brian frequently counsels clients in connection with the leasing and build out of specialized laboratory and manufacturing space. He has drafted and negotiated leases in major life sciences markets across the United States, including the Greater Boston/Cambridge areas, New Jersey, Philadelphia, Raleigh, San Diego and Seattle.
More about Brian
Chief Executive Officer
TheracosBio, LLC
- Lead a MA-based biotech company through the launch of an FDA-approved SGLT2 inhibitor for the treatment of Type 2 diabetes and the development of a pipeline of other products.
Co-Founder and Chief Operating Officer
IncreVet, Inc.
- Co-Founder and COO of IncreVet, Inc., an innovative animal health drug development company that developed the first FDA-approved oral treatment for feline diabetes before being acquired.
Senior Manager for Business Development
IDEXX Laboratories, Inc.
- IDEXX Laboratories, Inc. where he was both an Associate General Counsel in the company’s legal department and a Senior Manager for Business Development helping IDEXX grow its reference laboratory network through acquisitions both inside and outside the United States
Prior to joining IDEXX, Brian practiced law at a large Boston law firm, representing technology, life sciences, and software companies. Additionally, he served as legal counsel to the Committee on Education and the Workforce in the U.S. House of Representatives, served as legal counsel to the U.S. Senate's Committee on Governmental Affairs and clerked for the Honorable Clyde Hamilton of the United States Court of Appeals for the Fourth Circuit.
- Sale of Bio-Pharm, Inc. to Torrent Pharmaceuticals
- Merger of Motif Micro, Inc. to YPB Group Limited
- Sale of AesRx (with a Phase II sickle cell program) to Baxter International
- Alnylam Pharmaceuticals acquisition of Sirna Therapeutics from Merck for $175 million plus milestones and royalties
- Spin-out of Florida Biologix business from University of Florida, and equity financing
- Strategic investment from IMS Health in CliniWorks
- Spin-out and equity financing of Mellitus from Harvard Medical School
- Acquisition of PharmPro division of FluidAir by Mutual Pharmaceutical Company
- Business combination of BioSTAR West and Hawaii Chitopure to form Synedgen
- Long-Term Manufacturing and Supply Agreement between Bio- Pharm, Inc. and G&W Laboratories, Inc.
- Acquisition of all of the shares of Porogen Corporation by Air Liquide Advanced Technologies U.S. LLC (pending)
- Acquisition of all of the shares of Vgo Communications, Inc. by Vecna Technologies, Inc.
- Sale of a controlling interest in HighRes Biosolutions, Inc. to NewtrAx
Leasing Work
- Lease of approximately 66,000 RSF in Watertown, MA between Kala Pharmaceuticals, Inc. and 480 Arsenal Group, LLC
- Lease of approximately 38,000 RSF in Cambridge, MA between Unum Therapeutics, Inc. and King Street Properties
- Lease of approximately 15,000 RSF HQ office and Warehouse space in Nassau, NY between Level Solar, Inc. and Steel 327 New South Road LLC
- Lease of approximately 48,500 RSF of space in Cambridge, MA between Alnylam, Inc. and RREEF America REIT II CORP
- Lease of approximately 4,800 RSF of office space in Seattle, WA between Atara Biotherapeutics, Inc. and BPG Rock Westlake, LLC
- Lease of approximately 3,500 RSF of office space in King of Prussia, PA between Paratek Pharma LLC and Atlantic American Properties Trust
- Lease of approximately 37,500 RSF of office and lab space in Cambridge, MA between Dicerna Pharmaceuticals, Inc. and King Street Properties
- Lease of approximately 46,000 RSF of office and lab space in Waltham, MA between NetBio, Inc. and 266 & 275 Second Avenue, LLC
- Lease of approximately 5,200 RSF of office space in Billerica, MA between Raindance Technologies, Inc. and Fortune Partners, LC
Chief Executive Officer
TheracosBio, LLC
- Lead a MA-based biotech company through the launch of an FDA-approved SGLT2 inhibitor for the treatment of Type 2 diabetes and the development of a pipeline of other products.
Co-Founder and Chief Operating Officer
IncreVet, Inc.
- Co-Founder and COO of IncreVet, Inc., an innovative animal health drug development company that developed the first FDA-approved oral treatment for feline diabetes before being acquired.
Senior Manager for Business Development
IDEXX Laboratories, Inc.
- IDEXX Laboratories, Inc. where he was both an Associate General Counsel in the company’s legal department and a Senior Manager for Business Development helping IDEXX grow its reference laboratory network through acquisitions both inside and outside the United States
Prior to joining IDEXX, Brian practiced law at a large Boston law firm, representing technology, life sciences, and software companies. Additionally, he served as legal counsel to the Committee on Education and the Workforce in the U.S. House of Representatives, served as legal counsel to the U.S. Senate's Committee on Governmental Affairs and clerked for the Honorable Clyde Hamilton of the United States Court of Appeals for the Fourth Circuit.
- Sale of Bio-Pharm, Inc. to Torrent Pharmaceuticals
- Merger of Motif Micro, Inc. to YPB Group Limited
- Sale of AesRx (with a Phase II sickle cell program) to Baxter International
- Alnylam Pharmaceuticals acquisition of Sirna Therapeutics from Merck for $175 million plus milestones and royalties
- Spin-out of Florida Biologix business from University of Florida, and equity financing
- Strategic investment from IMS Health in CliniWorks
- Spin-out and equity financing of Mellitus from Harvard Medical School
- Acquisition of PharmPro division of FluidAir by Mutual Pharmaceutical Company
- Business combination of BioSTAR West and Hawaii Chitopure to form Synedgen
- Long-Term Manufacturing and Supply Agreement between Bio- Pharm, Inc. and G&W Laboratories, Inc.
- Acquisition of all of the shares of Porogen Corporation by Air Liquide Advanced Technologies U.S. LLC (pending)
- Acquisition of all of the shares of Vgo Communications, Inc. by Vecna Technologies, Inc.
- Sale of a controlling interest in HighRes Biosolutions, Inc. to NewtrAx
Leasing Work
- Lease of approximately 66,000 RSF in Watertown, MA between Kala Pharmaceuticals, Inc. and 480 Arsenal Group, LLC
- Lease of approximately 38,000 RSF in Cambridge, MA between Unum Therapeutics, Inc. and King Street Properties
- Lease of approximately 15,000 RSF HQ office and Warehouse space in Nassau, NY between Level Solar, Inc. and Steel 327 New South Road LLC
- Lease of approximately 48,500 RSF of space in Cambridge, MA between Alnylam, Inc. and RREEF America REIT II CORP
- Lease of approximately 4,800 RSF of office space in Seattle, WA between Atara Biotherapeutics, Inc. and BPG Rock Westlake, LLC
- Lease of approximately 3,500 RSF of office space in King of Prussia, PA between Paratek Pharma LLC and Atlantic American Properties Trust
- Lease of approximately 37,500 RSF of office and lab space in Cambridge, MA between Dicerna Pharmaceuticals, Inc. and King Street Properties
- Lease of approximately 46,000 RSF of office and lab space in Waltham, MA between NetBio, Inc. and 266 & 275 Second Avenue, LLC
- Lease of approximately 5,200 RSF of office space in Billerica, MA between Raindance Technologies, Inc. and Fortune Partners, LC
Related Content
Interested in working with Brian?
Our team is eager to learn more about your project